Article
JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group.
British journal of haematology - 1 Jul 2018
Aynardi Jason, Manur Rashmi, Hess Paul R, Chekol Seble, Morrissette Jennifer J D, Babushok Daria, Hexner Elizabeth, Rogers Heesun J, Hsi Eric D, Margolskee Elizabeth, Orazi Attilio, Hasserjian Robert, Bagg Adam
Abstract excerpt
The JAK2 V617F mutation is characteristic of most Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) and occurs rarely in de novo acute myeloid leukaemia (AML). We sought to characterize AMLs that harbour this mutation and distinguish those that arise de novo (AML-DN) from those that reflect transformation of an underlying MPN (AML-MPN). Forty-five patients with JAK2 V617F-mutated AML were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.